General MedicationsINTRATHECALGeneric
OSMOVIST 190
IOTROLAN
Standard Dose
40.6%
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview OSMOVIST 190 is listed in Drugs@FDA under application 019580 (NDA).
Marketing status: Discontinued Active ingredient IOTROLAN Form and strength INJECTABLE;INTRATHECAL - 40.6% Sponsor BAYER HLTHCARE Submission history See approval history documents.
Structured Monograph
Clinical summary
Approval overview OSMOVIST 190 is listed in Drugs@FDA under application 019580 (NDA). Marketing status: Discontinued Active ingredient IOTROLAN Form and strength INJECTABLE;INTRATHECAL - 40.6% Sponsor BAYER HLTHCARE Submission history See approval history documents.
Monitoring
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.